Shares of AstraZeneca PLC AZN shed 1.66% to £104.50 Friday, on what proved to be an all-around dismal trading session for the ...

AstraZeneca PLC closed 20.63% short of its 52-week high of £133.88, which the company achieved on September 3rd.

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

(Reuters) -AstraZeneca CEO Pascal Soriot is considering moving the company's stock market listing to the U.S., the Times ...

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...

AstraZeneca outperforms markets YTD amid eased concerns, China clarity, minimal US tariff impact, and attractive valuations.

AstraZeneca is interested in acquiring small and mid-sized companies specialising in oncology and cardiovascular treatments, Chief Executive Pascal Soriot said in a Reuters Newsmaker interview on ...

AstraZeneca is reportedly considering moving its listing to the US. Here's why AZN's expected departure is alarming for the ...

Compared to the aggregate P/E ratio of 27.38 in the Pharmaceuticals industry, AstraZeneca Inc. has a higher P/E ratio of ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition. Find out why AZN stock is a hold.

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...